Adherence to antiparkinson medication in a multicenter European study

• DOI: 10.1002/mds.22112
• Publication Date: 2009-02-03T22:09:48Z
• Authors: Donald Grosset; Angelo Antonini; Margherita Canesi; Gianni Pezzoli; Andrew Lees; Karen Shaw; Esther Cubo; Pablo Martinez‐Ma...; Olivier Rascol; Laurence Negre‐Pages; Ana Senard; Johannes Schwarz; Karl Strecker; Heinz Reichmann; Alexander Storch; Matthias Löhle; Fabrizio Stocchi; Katherine Grosset
• Keywords: Interquartile range; Demographics

Abstract Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. disease patients taking dopaminergic were enrolled 8 centers 5 countries, and severity demographics recorded. Antiparkinson drug was measured for 4 weeks using electronic monitoring bottles which record the date time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with 7.7 (SD 8.2) completed study. Total median (doses taken/doses prescribed) 97.7% (interquartile range [IQ] 90.6–100), days (correct dose days) 86.2% (IQ 61.1–96.2) timing taken at correct intervals) 24.4% 5.3–56.5). Fourteen (12.5%) took less than 80% prescribed doses, defined as adherence. Patients satisfactory mg/day 0–33) their levodopa ( P = NS), while 481 205–670) 0.0006). The Parkinson motor score significantly higher 29 20–40), versus those 19 13–26), 0.005. Once daily drugs had better when compared more frequently < 0.0001). Suboptimal is associated significant from despite greater severity. Optimizing oral medication intake has potential role maximizing response © 2009 Movement Disorder Society